Med2Date — Clinical Guidelines
Home Family Medicine Diabetes Mellitus

Diabetes Mellitus

Last updated 31 May 2026 · Endocrinology

📋 Key Information Summary

📋
  • Type 1 diabetes results from autoimmune destruction of pancreatic β-cells, typically presenting in childhood/adolescence with absolute insulin deficiency; Type 2 diabetes involves insulin resistance with progressive β-cell failure, accounting for ~85–90% of cases in Australia.
  • Diagnosis is confirmed by HbA1c ≥6.5% (48 mmol/mol), fasting venous plasma glucose ≥7.0 mmol/L, 2-hour OGTT ≥11.1 mmol/L, or random glucose ≥11.1 mmol/L with classic symptoms — two abnormal results from the same or different samples required unless unequivocal hyperglycaemia.
  • Over 1.3 million Australians live with diabetes; it is the 7th leading cause of death nationally and the leading cause of preventable blindness, end-stage kidney disease, and non-traumatic lower-limb amputation.
  • Aboriginal and Torres Strait Islander peoples experience diabetes at 3–4 times the rate of non-Indigenous Australians, with earlier onset, higher complication rates, and greater mortality — culturally safe, community-led care is essential.
  • Screening for Type 2 diabetes should begin at age 18 (or earlier in high-risk groups) using the Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) score ≥12, or age ≥40 with any risk factor.
  • Gestational diabetes mellitus (GDM) affects 12–14% of pregnancies in Australia; universal screening is recommended at 24–28 weeks using a 75 g OGTT per ADIPS 2014 criteria.
  • First-line pharmacotherapy for Type 2 diabetes is metformin (PBS General Benefit) alongside structured lifestyle modification; SGLT2 inhibitors or GLP-1 receptor agonists are added early when cardiovascular disease, heart failure, or chronic kidney disease coexists.
  • HbA1c target is generally <7.0% (53 mmol/mol) for most adults; individualised targets of <6.5% or <8.0% apply in younger patients or those with comorbidities/frailty respectively.
  • All patients with diabetes should receive an annual cycle of care (MBS items 721/723 + 2517), including HbA1c, lipids, eGFR, urine ACR, retinal screening, foot examination, and cardiovascular risk assessment.
  • Diabetic ketoacidosis (DKA) is a medical emergency requiring IV fluid resuscitation, fixed-rate IV insulin infusion (0.1 units/kg/hr), and potassium monitoring — hospital admission is mandatory.
  • Insulin remains the cornerstone of Type 1 diabetes management (multiple daily injections or continuous subcutaneous insulin infusion); all insulin preparations are PBS-listed.
  • Structured self-monitoring of blood glucose (SMBG), continuous glucose monitoring (CGM) devices, and diabetes education (including credentialled diabetes educators) are integral to achieving glycaemic targets and reducing hypoglycaemia risk.

Introduction & Australian Epidemiology

Diabetes mellitus is a group of chronic metabolic disorders characterised by persistent hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. In Australian general practice, diabetes is one of the most commonly managed chronic conditions, with an estimated 1.3 million Australians currently living with the disease and a further 500,000 undiagnosed. The condition accounts for approximately 11% of the Australian health burden and is the leading cause of preventable blindness, end-stage kidney disease (ESKD), and non-traumatic lower-limb amputation.

The Australian Institute of Health and Welfare (AIHW) reports that diabetes prevalence has tripled over the past two decades, driven primarily by the rising incidence of Type 2 diabetes in the context of increasing obesity, sedentary behaviour, and population ageing. The direct healthcare cost of diabetes exceeds billion annually, with indirect costs (lost productivity, carer burden) estimated at a further billion.

Diabetes disproportionately affects Aboriginal and Torres Strait Islander peoples, those in lower socioeconomic areas, and people in rural and remote communities. The burden of complications — retinopathy, neuropathy, nephropathy, and cardiovascular disease — is significantly higher in these groups, reflecting disparities in access to preventive care, specialist services, and culturally appropriate health programmes.

This guideline provides a comprehensive, evidence-based framework for the identification, diagnosis, and management of diabetes mellitus in Australian primary care, with a focus on practical implementation, PBS-relevant prescribing, and equitable care for all Australians.

Parameter Value
Estimated Australians with diabetes ~1.3 million (diagnosed)
Estimated undiagnosed Type 2 diabetes ~500,000
Type 2 diabetes proportion ~85–90% of all diabetes
Type 1 diabetes proportion ~10–12%
GDM prevalence 12–14% of pregnancies
ATSI vs non-Indigenous prevalence ratio 3–4 times higher
Diabetes as % of total disease burden (DALY) ~11%

Pathophysiology

Understanding the pathophysiology of the major diabetes subtypes is essential for accurate diagnosis and appropriate treatment selection.

Type 1 Diabetes — Autoimmune β-Cell Destruction

Type 1 diabetes (T1DM) is caused by T-cell-mediated autoimmune destruction of insulin-producing β-cells in the pancreatic islets of Langerhans. The process is triggered in genetically susceptible individuals (HLA-DR3, HLA-DR4, HLA-DQ2, HLA-DQ8) by environmental factors that may include viral infections (enteroviruses, coxsackievirus B), dietary proteins, and gut microbiome changes. Islet cell antibodies (ICA), glutamic acid decarboxylase antibodies (GAD65), insulinoma-associated antigen-2 antibodies (IA-2A), zinc transporter 8 antibodies (ZnT8A), and insulin autoantibodies (IAA) are detectable months to years before clinical onset. By the time symptoms appear, approximately 80–90% of β-cell mass has been destroyed. Residual C-peptide production is minimal or absent, resulting in absolute insulin deficiency and a lifelong requirement for exogenous insulin.

Type 2 Diabetes — Insulin Resistance & Progressive β-Cell Failure

Type 2 diabetes (T2DM) develops through a dual defect: peripheral insulin resistance (primarily in skeletal muscle, liver, and adipose tissue) and a progressive decline in β-cell insulin secretory capacity. Visceral adiposity drives insulin resistance via increased free fatty acids, pro-inflammatory adipokines (TNF-α, IL-6), and ectopic lipid deposition in liver and muscle. The liver exhibits increased gluconeogenesis and reduced glycogen storage, while skeletal muscle demonstrates impaired glucose uptake. Initially, β-cells compensate with hyperinsulinaemia; over time, β-cell exhaustion, glucotoxicity, lipotoxicity, and amyloid deposition (islet amyloid polypeptide) lead to declining insulin secretion and overt hyperglycaemia. Genetic predisposition is strong (TCF7L2, KCNJ11, PPARG polymorphisms), and epigenetic modifications from in-utero undernutrition or overnutrition contribute to intergenerational risk.

Other Specific Types

Latent autoimmune diabetes of adults (LADA) shares autoimmune features with T1DM but has a slower onset, typically presenting after age 30 with initial insulin independence. Maturity-onset diabetes of the young (MODY) encompasses monogenic forms (particularly HNF1A-MODY and GCK-MODY) with autosomal dominant inheritance. Secondary causes include chronic pancreatitis, cystic fibrosis-related diabetes (CFRD), haemochromatosis, Cushing syndrome, and drug-induced diabetes (corticosteroids, atypical antipsychotics, tacrolimus).

Type 1 vs Type 2 Differentiation

Accurate differentiation between Type 1 and Type 2 diabetes is critical as it determines the treatment approach, monitoring strategy, and patient education focus. Misclassification is common, particularly in adults presenting with Type 1 diabetes or children/adolescents with Type 2 diabetes.

⚠️
Clinical pitfall: Approximately 5–10% of adults initially diagnosed with Type 2 diabetes actually have LADA (slowly progressive Type 1). Consider autoantibody testing (GAD65, IA-2A) in any adult with T2DM features who is lean, has a personal or family history of autoimmune disease, or fails to respond to oral hypoglycaemic agents within 2–3 years.
Feature Type 1 Diabetes Type 2 Diabetes
Typical age of onset Childhood/adolescence (peak 4–6 yrs & 10–14 yrs); any age Usually >40 yrs; increasingly in adolescents/young adults
Onset Acute (days to weeks) Insidious (months to years)
Body habitus Usually lean/normal weight Usually overweight/obese (BMI ≥25)
Autoantibodies Positive (GAD65, IA-2A, ZnT8, ICA, IAA) Negative
C-peptide Low or undetectable Normal, elevated, or low (late disease)
Ketosis prone Yes — DKA common at presentation Rare (HHNS more typical)
Family history Weak (concordance ~50% in identical twins) Strong (concordance ~90% in identical twins)
Associated autoimmune conditions Coeliac disease, thyroid disease, Addison disease, pernicious anaemia Metabolic syndrome, NAFLD, PCOS, obstructive sleep apnoea
Initial treatment Insulin from diagnosis — lifelong Lifestyle ± metformin; step-up therapy
Honeymoon period Yes (transient partial remission weeks to months) Not applicable

When to Suspect Type 1 in Adults

  • Age <50 with acute symptomatic presentation (polyuria, polydipsia, weight loss)
  • BMI <25 kg/m² at diagnosis
  • Personal or family history of autoimmune disease (thyroid, coeliac, vitiligo)
  • Rapid progression to insulin requirement within months of diagnosis
  • History of diabetic ketoacidosis

When to Suspect Type 2 in Children/Adolescents

  • Obesity (BMI ≥85th percentile for age) with acanthosis nigricans
  • Strong family history of T2DM (particularly first-degree relatives)
  • Ethnicity — Aboriginal and Torres Strait Islander, Pacific Islander, South Asian, Māori
  • Polycystic ovary syndrome in adolescent females
  • No ketosis; C-peptide normal or elevated; autoantibodies negative

Key Investigations for Differentiation

Essential GAD65 antibodies (anti-glutamic acid decarboxylase) Most sensitive single antibody test for T1DM. Positive in ~70–80% at diagnosis. MBS item 66831. Available through major pathology laboratories nationwide.
Available IA-2A (insulinoma-associated antigen-2 antibodies) Positive in ~60% of new-onset T1DM. Combined with GAD65 increases sensitivity to >90%. Available at major labs.
Available ZnT8 antibodies (zinc transporter 8) Useful when GAD65 and IA-2A are negative but clinical suspicion for T1DM is high. Available at specialist/reference laboratories.
Essential Fasting C-peptide / stimulated C-peptide Low or undetectable (<0.2 nmol/L fasting) in T1DM. Normal or elevated in T2DM. MBS item 66836. Measure in non-acutely unwell patients after at least 3 months of diabetes duration.

Screening, Diagnosis & Risk Factors

Screening for Type 2 Diabetes

The RACGP and Diabetes Australia recommend opportunistic screening for Type 2 diabetes in all adults from age 18 years, with the frequency and intensity of screening guided by individual risk. The Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK) is a validated 12-point questionnaire recommended for use in general practice to identify individuals at increased risk.

💡
AUSDRISK Score Interpretation: A score ≥12 indicates high risk — proceed to pathology testing. A score of 5–11 indicates moderate risk — recommend lifestyle modification and re-screen within 3 years. A score <5 indicates low risk — re-screen every 3 years or sooner if symptoms develop.

Groups requiring screening regardless of AUSDRISK score:

  • All Aboriginal and Torres Strait Islander adults from age 18 years
  • All adults aged ≥40 years
  • Women with a history of gestational diabetes — lifelong screening every 1–2 years
  • Women with polycystic ovary syndrome
  • First-degree relatives of people with Type 2 diabetes
  • People with cardiovascular disease (coronary, cerebrovascular, peripheral vascular)
  • People with overweight/obesity (BMI ≥25, or ≥23 in Asian-background populations)
  • People with metabolic syndrome (central obesity + ≥2 of dyslipidaemia, hypertension, impaired glucose)
  • People on medications associated with hyperglycaemia (corticosteroids, atypical antipsychotics, tacrolimus, cyclosporine)
  • People with severe mental illness (schizophrenia, bipolar disorder)
  • People with non-alcoholic fatty liver disease (NAFLD)

Diagnostic Criteria

Diagnosis of diabetes requires at least one of the following confirmed on a second occasion (unless unequivocal hyperglycaemia with acute metabolic decompensation):

Test Diabetes High Risk (Pre-diabetes) Normal
HbA1c ≥6.5% (48 mmol/mol) 6.0–6.4% (42–47 mmol/mol) <6.0% (<42 mmol/mol)
Fasting venous plasma glucose ≥7.0 mmol/L 6.1–6.9 mmol/L (IFG) <6.1 mmol/L
2-hour OGTT (75 g glucose) ≥11.1 mmol/L 7.8–11.0 mmol/L (IGT) <7.8 mmol/L
Random venous plasma glucose ≥11.1 mmol/L + classic symptoms — —
⚠️
HbA1c limitations: HbA1c is unreliable in conditions affecting red cell turnover — haemolytic anaemia, chronic kidney disease (eGFR <30), haemoglobinopathies (HbS, HbC, HbF), iron deficiency anaemia, recent blood transfusion, pregnancy (first/second trimester), and haemolytic disease. In these situations, use fasting glucose and/or OGTT. Point-of-care HbA1c devices should not be used for diagnosis.

MBS items for screening and diagnosis:

  • MBS 66500 — Fasting blood glucose (venous plasma)
  • MBS 66841 — HbA1c (eligible if no HbA1c in preceding 3 months; one per 12-month period for monitoring, unrestricted for diagnostic purposes)
  • MBS 66843 — Oral glucose tolerance test (75 g, 2-hour)
  • MBS 66836 — C-peptide (for subtype differentiation)
  • MBS 66831 — Islet cell/anti-GAD antibodies (for subtype differentiation)

Risk Factors for Type 2 Diabetes

Non-modifiable Modifiable
Age ≥40 years Overweight/obesity (BMI ≥25)
Aboriginal and Torres Strait Islander descent Central obesity (waist >94 cm men, >80 cm women)
First-degree relative with T2DM Physical inactivity (<150 min/week moderate activity)
History of GDM Unhealthy diet (high glycaemic index, processed foods)
Ethnicity (South Asian, Pacific Islander, Māori, Middle Eastern) Smoking
Polycystic ovary syndrome Hypertension (≥140/90 mmHg)
History of cardiovascular disease Dyslipidaemia (HDL <1.0 or triglycerides >2.0 mmol/L)
Antipsychotic medication use Impaired glucose tolerance/impaired fasting glucose on prior testing

Clinical Presentation

Type 1 Diabetes

Type 1 diabetes typically presents acutely with classic osmotic symptoms: polyuria, polydipsia, nocturia, unexplained weight loss, fatigue, and blurred vision. In children, presentation may include secondary nocturnal enuresis, abdominal pain, and behavioural changes. Up to 25% of new-onset T1DM in children presents with diabetic ketoacidosis (DKA) — a medical emergency characterised by nausea, vomiting, Kussmaul breathing, fruity breath odour, and altered consciousness.

Type 2 Diabetes

Type 2 diabetes is often asymptomatic for years and may be detected incidentally on routine blood tests. When symptoms develop, they are typically insidious: fatigue, recurrent infections (particularly candidiasis, urinary tract infections, skin infections), slow wound healing, paraesthesiae, and erectile dysfunction. Up to 50% of people with T2DM already have one or more complications at the time of diagnosis, reflecting a prolonged period of undetected hyperglycaemia.

Acute Presentations

Mild
Asymptomatic / Mild Symptomatic
Elevated blood glucose found incidentally. Mild osmotic symptoms (polydipsia, polyuria). No metabolic decompensation. Alert and oriented.
Setting: GP clinic — routine or opportunistic diagnosis
Moderate
Symptomatic Hyperglycaemia
Persistent osmotic symptoms, weight loss, fatigue, recurrent infections. BGL often >15 mmol/L. No ketoacidosis or hyperosmolar state. May have intercurrent illness.
Setting: Urgent GP review ± same-day endocrinology referral
Severe
DKA or Hyperosmolar Hyperglycaemic State (HHS)
DKA: BGL >11 mmol/L, ketonaemia >3 mmol/L or ketonuria ++/+++, pH <7.3, bicarbonate <15. Nausea, vomiting, Kussmaul breathing, altered consciousness. HHS: BGL often >30 mmol/L, serum osmolality >320 mOsm/kg, profound dehydration, no significant ketosis. Usually in elderly T2DM.
Setting: Emergency department — immediate resuscitation and ICU/HDU admission
🚨
DKA is a medical emergency. Suspect DKA in any patient with known or suspected diabetes who presents with nausea, vomiting, abdominal pain, rapid breathing, or altered consciousness. Commence IV 0.9% NaCl bolus, check BGL and blood ketones urgently, and arrange immediate transfer to the emergency department. Do not delay for outpatient investigations.

Investigations

Baseline Investigations at Diagnosis

Essential HbA1c Diagnostic and baseline. MBS 66841. Repeat every 3–6 months for monitoring. One per 12-month period covered by MBS for monitoring (additional tests for clinical indication).
Essential Fasting lipid profile Total cholesterol, HDL, LDL, triglycerides. Part of cardiovascular risk assessment. MBS 66551/66552. Repeat annually or as guided by treatment.
Essential Renal function — eGFR + urine albumin-to-creatinine ratio (ACR) eGFR (serum creatinine, MBS 66503) and urine ACR (MBS 66837) to screen for diabetic kidney disease. Repeat annually. Abnormal ACR confirmed on 2 of 3 samples over 3–6 months.
Essential Full blood examination (FBE) Baseline FBE to exclude anaemia (which may affect HbA1c interpretation) and assess general health. MBS 65070.
Essential Liver function tests (LFTs) Baseline LFTs prior to commencing metformin or statin therapy. Also screens for NAFLD (AST:ALT ratio, GGT). MBS 66503.
Essential Thyroid function tests (TFTs) Screen for thyroid dysfunction, which is common in T1DM (autoimmune association) and may affect glycaemic control. MBS 66716.
Available Coeliac serology (anti-tTG IgA) Recommended at diagnosis of T1DM (prevalence ~5–10%). Repeat every 2–3 years or if symptomatic. MBS 66832.
Available GAD65 / IA-2A / ZnT8 antibodies For subtype differentiation (Type 1 vs LADA vs Type 2). MBS 66831.
Available Fasting C-peptide Confirms endogenous insulin production. Low/absent in T1DM. MBS 66836.

Annual Cycle of Care Investigations

Under the MBS Chronic Disease Management items (721 GPMP, 723 TCA, and 2517 annual review), patients with diabetes should receive the following annually at minimum:

  • HbA1c (every 3–6 months; MBS 66841)
  • eGFR and urine ACR
  • Lipid profile
  • Blood pressure measurement
  • Weight, waist circumference, BMI
  • Comprehensive foot examination (monofilament, tuning fork, pedal pulses)
  • Retinal screening — dilated fundoscopy or digital retinal photography (MBS 12320/12321 for ophthalmologist; bulk-billed through state screening programmes in some jurisdictions)
  • Assessment of diabetes self-management education needs
  • Review of medications and adherence
  • Psychological wellbeing screening (PHQ-9, K10)
  • Smoking status and cessation support

Self-Monitoring of Blood Glucose (SMBG)

SMBG is essential for all patients on insulin therapy and recommended for those on sulfonylureas or with variable glycaemic control. Blood glucose test strips are available under the National Diabetes Services Scheme (NDSS) — registration is free for all Australians with a confirmed diabetes diagnosis. CGM devices (e.g., Freestyle Libre, Dexcom G7) are increasingly PBS-subsidised for eligible patients (see Monitoring section).

Risk Stratification & Glycaemic Targets

Glycaemic targets should be individualised based on patient characteristics, risk of hypoglycaemia, diabetes duration, life expectancy, comorbidities, and patient preference. The following framework guides target-setting in Australian practice:

Lower Target
HbA1c <6.5% (48 mmol/mol)
Young adults, newly diagnosed T2DM, T1DM with technology-assisted management, low hypoglycaemia risk, no significant comorbidities. Pre-conception planning.
Setting: Close monitoring; avoid if recurrent hypoglycaemia
Standard Target
HbA1c <7.0% (53 mmol/mol)
Most adults with T1DM or T2DM. Provides optimal balance between microvascular risk reduction and hypoglycaemia. Default target unless individual factors dictate otherwise.
Setting: General practice — annual review with HbA1c every 3–6 months
Relaxed Target
HbA1c <8.0% (64 mmol/mol)
Elderly, frail, limited life expectancy, extensive comorbidities, recurrent severe hypoglycaemia, hypoglycaemia unawareness, advanced microvascular/macrovascular complications. Avoid overtreatment.
Setting: Multidisciplinary team — consider deprescribing where appropriate

Cardiovascular Risk Assessment

All adults with diabetes aged ≥45 years (≥35 years for Aboriginal and Torres Strait Islander peoples) should have a formal cardiovascular risk assessment using the Australian Cardiovascular Risk Calculator (AusCVRisk / QRISK3 adapted for Australian populations). People with diabetes are automatically classified as at least "intermediate risk" — many are "high risk" based on the presence of additional risk factors. Absolute cardiovascular risk (ACVR) assessment guides the intensity of lipid-lowering and antihypertensive therapy.

💡
Automatically HIGH cardiovascular risk: Type 2 diabetes with any of — eGFR <60, urine ACR ≥30 mg/g, diabetic retinopathy, neuropathy, or duration >10 years. Type 1 diabetes with duration >20 years or any microvascular complication. Consider high-intensity statin for all.

Management & Monitoring

Lifestyle Modification — Foundation of All Diabetes Management

Structured lifestyle intervention is the cornerstone of Type 2 diabetes management and an important adjunct in Type 1 diabetes. Evidence from the Finnish Diabetes Prevention Study and the Diabetes Prevention Program demonstrates that intensive lifestyle modification reduces progression from pre-diabetes to diabetes by 58%.

1
Nutrition
Individualised medical nutrition therapy (MNT) with an accredited practising dietitian (APD). Emphasise Mediterranean-style eating pattern, low glycaemic index foods, high fibre (≥25 g/day), reduced saturated fat, and portion control. Refer via GPMP/TCA for Medicare rebates. No single "diabetic diet" — cultural and socioeconomic factors must be considered.
2
Physical Activity
≥150 minutes/week of moderate-intensity aerobic exercise (brisk walking, cycling, swimming) + resistance training ≥2 days/week. Reduce prolonged sitting (break every 30 minutes). Exercise improves insulin sensitivity, cardiovascular fitness, and mental health. Individualised exercise prescription for those with complications (retinopathy — avoid Valsalva; neuropathy — appropriate footwear).
3
Weight Management
Target ≥5% weight loss in overweight/obese T2DM improves HbA1c, blood pressure, and lipids. Consider structured programmes (e.g., CSIRO Total Wellbeing Diet, Diabetes Australia programmes). For BMI ≥40 or BMI ≥35 with poorly controlled T2DM, discuss bariatric/metabolic surgery referral. Intensive weight-loss pharmacotherapy (semaglutide, tirzepatide) has dual glycaemic and weight benefits.
4
Alcohol & Smoking
Alcohol: ≤10 standard drinks/week; avoid drinking on an empty stomach (hypoglycaemia risk with insulin/sulfonylureas). Smoking cessation: every opportunity — offer NRT, varenicline, or bupropion (all PBS-listed). Smoking doubles cardiovascular risk in diabetes.
5
Diabetes Education
Refer to a credentialled diabetes educator (CDE) and/or structured group programme (e.g., DESMOND, X-PERT, COACH). Self-management education improves outcomes. Available via Diabetes Australia, hospitals, community health centres, and telehealth (particularly for rural/remote patients).

Pharmacological Management — Type 2 Diabetes

Pharmacotherapy for T2DM follows a stepwise approach, with metformin as first-line and escalation guided by HbA1c response, patient characteristics, comorbidities (cardiovascular disease, heart failure, CKD), and PBS criteria.

First-Line Therapy

💊
Metformin
Diaformin®, Glucophage® · Biguanide
Mechanism Reduces hepatic glucose production; improves insulin sensitivity; does not cause hypoglycaemia as monotherapy
Adult dose Start 500 mg PO OD–BD with food; titrate over 2–4 weeks to 1 g BD (max 2–2.5 g/day in divided doses). Extended-release (XR) formulation for GI side effects: 500 mg–2 g OD with evening meal.
Renal adjustment eGFR 30–45: reduce dose (max 1 g/day); eGFR <30: contraindicated. Review dose if eGFR declining. Contrast imaging: withhold 48 hours post iodinated contrast if eGFR <60.
Hepatic adjustment Avoid in significant hepatic impairment (risk of lactic acidosis). Caution with alcohol excess.
Key side effects GI — nausea, diarrhoea, bloating (minimised by slow titration and XR formulation). Vitamin B12 deficiency with long-term use (check B12 every 2–3 years).
PBS status ✔ PBS General Benefit

Second-Line & Add-On Agents

The choice of second-line agent is guided by comorbidities, weight, hypoglycaemia risk, renal function, cost, and PBS availability.

💊
Empagliflozin
Jardiance® · SGLT2 inhibitor
Adult dose 10 mg PO OD; may increase to 25 mg OD. Effective for glucose, BP, weight, heart failure, and CKD progression.
Renal adjustment Initiate if eGFR ≥20 (cardio-renal benefits); glycaemic efficacy reduced below eGFR ~45. Not for glucose-lowering if eGFR <30, but may continue for cardio-renal protection.
Key warnings Genital mycotic infections (10–15%). Euglycaemic DKA risk (withhold 3–4 days before major surgery). Volume depletion/orthostatic hypotension. Fournier gangrene (rare but serious). Lower limb amputations (originally flagged with canagliflozin; empagliflozin data more favourable).
PBS status 🔶 PBS Authority Required — T2DM with inadequate glycaemic control on metformin AND cardiovascular disease OR as add-on to metformin + sulfonylurea
💊
Dapagliflozin
Forxiga® · SGLT2 inhibitor
Adult dose 10 mg PO OD. Similar efficacy and class effects to empagliflozin. Also indicated for chronic heart failure (with or without diabetes) and CKD.
Renal adjustment Initiate if eGFR ≥20. Glycaemic efficacy reduced at lower eGFR.
PBS status 🔶 PBS Authority Required — Similar criteria to empagliflozin
💊
Semaglutide
Ozempic® (injection), Rybelsus® (oral) · GLP-1 receptor agonist
Adult dose Subcutaneous: start 0.25 mg weekly ×4 weeks → 0.5 mg weekly ×4 weeks → 1 mg weekly (max 2 mg). Oral: 3 mg OD ×30 days → 7 mg OD ×30 days → 14 mg OD (max). Administer oral on empty stomach with ≤120 mL water, 30 min before food.
Key benefits HbA1c reduction 1.0–1.8%; weight loss 3–7 kg (up to 10+ kg with 2.4 mg). Cardiovascular risk reduction (SUSTAIN-6). Available as weekly subcutaneous or daily oral.
Key warnings GI side effects (nausea, vomiting, diarrhoea — usually transient). Pancreatitis risk (rare). Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2. Gastroparesis caution.
Renal adjustment No dose adjustment; caution with GI side effects causing dehydration.
PBS status 🔶 PBS Authority Required — T2DM with HbA1c ≥7% despite metformin + sulfonylurea or metformin + SGLT2i. Subject to clinical criteria.
💊
Liraglutide
Victoza® · GLP-1 receptor agonist
Adult dose Start 0.6 mg SC OD ×1 week → increase to 1.2 mg OD → may increase to 1.8 mg OD (max). Daily injection.
Key benefits Cardiovascular mortality reduction (LEADER trial). Good HbA1c reduction. Modest weight loss.
PBS status 🔶 PBS Authority Required — Similar criteria to semaglutide
💊
Sitagliptin
Januvia® · DPP-4 inhibitor
Adult dose 100 mg PO OD (50 mg if eGFR 30–45; 25 mg if eGFR <30). Weight neutral; does not cause hypoglycaemia as monotherapy.
Key limitations Modest HbA1c reduction (~0.5–0.8%). No demonstrated cardiovascular outcome benefit (TECOS trial — neutral). Less potent than GLP-1 RAs.
PBS status ✔ PBS General Benefit — T2DM as add-on to metformin or sulfonylurea
💊
Gliclazide
Diamicron®, Diamicron MR® · Sulfonylurea
Adult dose Standard: start 40–80 mg PO BD; max 160 mg BD. MR: 30 mg OD; titrate to 60–120 mg OD.
Key considerations Causes weight gain (+1–3 kg). Hypoglycaemia risk — particularly in elderly, renal impairment, and with alcohol. Lower hypoglycaemia risk vs glibenclamide. Avoid glibenclamide in the elderly.
Renal adjustment Use lower doses if eGFR <60. Caution — increased hypoglycaemia risk in renal impairment.
PBS status ✔ PBS General Benefit
💊
Pioglitazone
Actos® · Thiazolidinedione
Adult dose 15–30 mg PO OD; max 45 mg OD. Slow onset (4–12 weeks for full effect).
Key warnings Weight gain (+2–5 kg), fluid retention, heart failure exacerbation (contraindicated in NYHA III–IV). Increased fracture risk (especially in postmenopausal women). Possible increased bladder cancer risk (long-term data equivocal).
PBS status ✔ PBS General Benefit

Pharmacological Management — Type 1 Diabetes

All patients with Type 1 diabetes require lifelong insulin therapy. Modern management emphasises physiological insulin replacement using multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII — insulin pump).

💉
Rapid-Acting Insulin Analogues
NovoRapid® (aspart), Humalog® (lispro), Apidra® (glulisine)
Indication Prandial insulin — inject before meals (0–15 min before eating). Also used in insulin pumps (CSII).
Typical T1DM dose Initial total daily dose (TDD) 0.4–0.6 units/kg/day. ~50% as basal, ~50% as bolus divided across meals. Carbohydrate counting guides mealtime dosing (insulin-to-carbohydrate ratio, typically 1 unit per 10–15 g CHO). Correction/sensitivity factor calculated from TDD.
Onset / Peak / Duration Onset 10–20 min; peak 1–2 hours; duration 3–5 hours
PBS status ✔ PBS General Benefit — T1DM; Authority Required for T2DM
💉
Long-Acting Insulin Analogues
Lantus® (glargine 100), Levemir® (detemir), Toujeo® (glargine 300), Tresiba® (degludec)
Indication Basal insulin — provides 24-hour background insulin coverage. Glargine U100 and degludec given once daily; detemir may require BD dosing.
Typical T1DM dose 50% of TDD as basal; titrate based on fasting glucose target (4.4–7.0 mmol/L). Adjust by 1–2 units every 3 days.
Key differences Degludec (Tresiba): ultra-long duration (~42 hours), lowest hypoglycaemia risk, flexible dosing. Glargine U300 (Toujeo): more stable PK profile vs U100, less nocturnal hypoglycaemia.
PBS status ✔ PBS General Benefit — T1DM; Authority Required for T2DM
💉
Pre-Mixed Insulin
Mixtard® 30/70, NovoMix® 30, Humalog® Mix 25/50
Indication T2DM — simplified regimen for patients who cannot manage MDI. Usually BD (before breakfast and dinner). Not preferred in T1DM.
Key limitation Less physiological; more hypoglycaemia than MDI; less flexibility with meals. Consider conversion to basal-bolus if poorly controlled.
PBS status ✔ PBS General Benefit — T1DM; Authority Required for T2DM
✅
Continuous Glucose Monitoring (CGM) — PBS Subsidy Update: From 1 March 2024, CGM devices (Freestyle Libre 2/3, Dexcom G7) are available on the PBS as Authority Required for eligible patients with Type 1 diabetes, including those using insulin pumps. Eligibility includes T1DM patients aged ≥2 years with a valid Medicare card. CGM reduces HbA1c by 0.3–0.5% and significantly reduces time in hypoglycaemia. FreeStyle Libre also available through NDSS for eligible patients.

Monitoring Summary

Parameter Frequency Target / Notes
HbA1c Every 3–6 months <7.0% (53 mmol/mol) for most; individualise
Blood glucose (SMBG/CGM) Daily (insulin users); 2–4 times/week (non-insulin T2DM if SMBG) Fasting 4.4–7.0 mmol/L; postprandial <10.0 mmol/L
Blood pressure Every visit <130/80 mmHg (or individualised in elderly)
Lipid profile Annually (or 3-monthly after statin initiation) LDL <2.0 mmol/L for high CV risk; consider <1.4 for very high risk
eGFR + urine ACR Annually ACR <3.0 mg/mmol (normal); monitor for progression
Weight / BMI / waist Every visit BMI <25; waist <94 cm (M), <80 cm (F)
Foot examination Annually (every visit for high-risk feet) Monofilament, vibration, pulses, skin inspection
Retinal screening Every 2 years (annually if high risk) Digital retinal photography or ophthalmologist review
Psychosocial wellbeing Annually (PRN) PHQ-9, diabetes distress scales. Screen for diabetes burnout and eating disorders (diabulimia in T1DM).

Gestational Diabetes & Special Populations

Gestational Diabetes Mellitus (GDM)

GDM is defined as glucose intolerance first recognised during pregnancy, usually in the second or third trimester. It affects 12–14% of pregnancies in Australia and is associated with increased risks of pre-eclampsia, macrosomia, birth injuries, neonatal hypoglycaemia, and future Type 2 diabetes in both mother and offspring.

Screening

  • Universal screening is recommended for all pregnant women at 24–28 weeks' gestation using a 75 g OGTT per ADIPS 2014 criteria.
  • Earlier screening (first trimester) for high-risk women: previous GDM, BMI ≥35, age ≥40, family history of T2DM, PCOS, previous macrosomic baby (>4.5 kg), ethnicity (Aboriginal/Torres Strait Islander, South Asian, Middle Eastern, Pacific Islander, Māori), corticosteroid use.
  • If early OGTT is normal, repeat at 24–28 weeks.

ADIPS 2014 Diagnostic Criteria for GDM

OGTT Timepoint (75 g) Threshold
Fasting venous plasma glucose ≥5.1 mmol/L
1-hour venous plasma glucose ≥10.0 mmol/L
2-hour venous plasma glucose ≥8.5 mmol/L

One or more abnormal values is diagnostic of GDM.

GDM Management

  • Lifestyle: Dietary counselling (APD referral), moderate physical activity (≥30 min/day), blood glucose monitoring (fasting and 1-hour or 2-hour postprandial targets as per ADIPS).
  • Targets: Fasting <5.0 mmol/L; 1-hour postprandial <7.4 mmol/L; 2-hour postprandial <6.7 mmol/L.
  • Pharmacotherapy if targets not met within 1–2 weeks of lifestyle modification:
    • Metformin — safe in pregnancy; 500 mg BD titrating to 2.5 g/day. Crosses placenta but extensive safety data. Not PBS-listed for GDM (private prescription).
    • Insulin — remains the gold standard; all insulin types safe in pregnancy. Usually rapid-acting (aspart/lispro) + intermediate/long-acting (NPH or detemir — detemir has TGA category B3). Glargine (category C) used if needed but less preferred.
    • Glyburide/glibenclamide — used in some centres but not recommended first-line due to higher neonatal hypoglycaemia and macrosomia rates compared to metformin and insulin.
  • Postpartum: All women with GDM require a 75 g OGTT at 6–12 weeks postpartum, then every 1–3 years lifelong. Breastfeeding encouraged (improves maternal glucose metabolism).
⚠️
Pre-existing diabetes in pregnancy: Women with pre-existing T1DM or T2DM planning pregnancy require pre-conception counselling, conversion to insulin (if on oral agents), folic acid 5 mg/day for at least 1 month before conception, and target HbA1c <6.5% prior to conception. HbA1c is unreliable in the second and third trimesters — use fructosamine or CGM as adjuncts. Refer to endocrinologist and obstetrician with maternal-fetal medicine expertise.

Pre-Diabetes (Impaired Glucose Tolerance / Impaired Fasting Glucose)

Pre-diabetes (HbA1c 6.0–6.4%, IFG 6.1–6.9 mmol/L, IGT 7.8–11.0 mmol/L on OGTT) identifies individuals at high risk of progression to T2DM (5–10% per year) and cardiovascular events. Structured lifestyle intervention (weight loss ≥7%, ≥150 min/week physical activity) reduces progression by 58%. Metformin is not routinely recommended for pre-diabetes but may be considered for those with BMI ≥35, age <60, prior GDM, or progressive hyperglycaemia despite lifestyle changes.

Special Populations

👶

Paediatric Diabetes

T1DM accounts for >90% of paediatric diabetes in Australia. Diagnosis at any age, peak incidence 10–14 years. National Paediatric Diabetes Audit shows rising incidence (~3% per year).
Management: MDI (aspart + glargine/degludec) or insulin pump therapy (CSII). Target HbA1c <7.0% (ISPAD 2024). CGM strongly recommended (PBS-subsidised from age ≥2). Carbohydrate counting education for families.
T2DM in children: Rising incidence, particularly in Aboriginal and Torres Strait Islander and Pacific Islander youth. Metformin is first-line; insulin may be needed at diagnosis if ketosis present. Weight management is central.
Referral: All children with suspected diabetes should be referred to a paediatric endocrinologist. Regional centres (all states have tertiary paediatric diabetes services). Telehealth available for rural/remote families.
Key drugs: insulin aspart (NovoRapid), insulin glargine (Lantus), insulin degludec (Tresiba) — all PBS General Benefit for T1DM. Metformin (off-label in <10 years for T2DM; on-label from age 10).
👴

Elderly Patients (≥65 years)

Individualised HbA1c targets: Fit elderly: <7.0%; multimorbid: <8.0%; frail/limited life expectancy: <8.5% or symptom-based management. Avoid hypoglycaemia — associated with falls, fractures, cognitive decline, cardiac events.
Deprescribing: Review sulfonylureas and insulin regularly. Consider stopping agents in those with recurrent hypoglycaemia, limited life expectancy (<12 months), or who prioritise quality of life. Metformin and SGLT2 inhibitors preferred agents (low hypoglycaemia risk).
Renal dose adjustments are frequently needed — check eGFR every 3–6 months. Metformin contraindicated if eGFR <30. Avoid long-acting sulfonylureas (glibenclamide) — use gliclazide MR if needed.
Cognitive screening — diabetes self-management may be compromised by dementia. Involve carers; consider simplified regimens.
🫘

Renal Impairment

eGFR 60–90: No major dose adjustments; monitor regularly.
eGFR 45–60: Reduce metformin if trending down. SGLT2i continue (initiate for cardio-renal protection if eGFR ≥20). Review sulfonylureas.
eGFR 30–45: Metformin max 1 g/day. DPP-4i dose reduction (sitagliptin 50 mg). Avoid glibenclamide. SGLT2i may continue for renal protection.
eGFR <30: Cease metformin. Insulin may need dose reduction (decreased renal clearance). GLP-1 RAs safe but caution with GI side effects. Involve nephrology for co-management.
Dialysis (eGFR <15 or ESKD): HbA1c unreliable — use CGM or fructosamine. Insulin is main agent. Most oral agents ceased. Specialist management essential.
Finerenone (Kerendia) — non-steroidal MRA for T2DM with CKD (albuminuria + eGFR 25–90). Reduces CKD progression and CV events. PBS Authority Required.
🫁

Hepatic Impairment

NAFLD/NASH affects up to 70% of people with T2DM. Screen with LFTs and liver ultrasound. Pioglitazone has evidence for NASH resolution (despite being used less commonly in Australia). Weight loss ≥7–10% is the most effective intervention for NASH.
Cirrhosis: Metformin relatively contraindicated in decompensated cirrhosis (Child-Pugh C). Safe in compensated cirrhosis (Child-Pugh A–B). Insulin is preferred in advanced liver disease. Sulfonylureas carry risk of hypoglycaemia (impaired gluconeogenesis).
Hepatitis C: Direct-acting antiviral (DAA) treatment may improve insulin resistance and glycaemic control — monitor and adjust diabetes medications post SVR.
🛡️

Immunocompromised Patients

Transplant recipients: Post-transplant diabetes mellitus (PTDM) affects 10–30% of solid organ transplant recipients. Tacrolimus is a major risk factor. Manage with metformin (if renal function allows), DPP-4 inhibitors, or insulin. Avoid SGLT2 inhibitors in the early post-transplant period.
HIV: Increased T2DM risk (antiretroviral-related, lipodystrophy). Metformin and pioglitazone preferred. DPP-4 inhibitors have few drug interactions. Monitor with insulin if needed — consider lipohypertrophy risk with SC injections in lipodystrophic areas.
Corticosteroid-induced hyperglycaemia: Common with high-dose steroids. Monitor BGL in all patients on prednisolone ≥10 mg/day for >1 week. Treatment: rapid-acting insulin (breakfast dosing for morning prednisolone) or mixed insulin. SGLT2 inhibitors generally avoided during acute steroid courses.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health — Diabetes Mellitus

Diabetes mellitus is one of the most significant health challenges facing Aboriginal and Torres Strait Islander peoples. The AIHW reports that Indigenous Australians are 3.3 times more likely to have diabetes than non-Indigenous Australians, with the disparity greatest in the 35–44 year age group (6 times higher). Diabetes is the second leading contributor to the health gap between Indigenous and non-Indigenous Australians.

🚨
Key disparities: Aboriginal and Torres Strait Islander peoples experience diabetes onset 10–20 years earlier, are 3–4 times more likely to be hospitalised for diabetes, have 6–12 times higher rates of end-stage kidney disease due to diabetic nephropathy, and have significantly higher rates of diabetes-related amputation and blindness compared to non-Indigenous Australians.

Risk Factors Unique to or Amplified in Indigenous Populations

  • Earlier onset of T2DM — screening recommended from age 18 (or earlier if risk factors present)
  • High prevalence of obesity in children and adolescents
  • Limited access to fresh, affordable, nutritious food in remote communities ("food insecurity")
  • Intergenerational effects of in-utero hyperglycaemia (foetal programming)
  • Higher prevalence of rheumatic heart disease and chronic kidney disease, complicating management
  • Higher smoking rates contributing to accelerated cardiovascular disease
  • Social determinants of health — housing, education, employment, incarceration, racism, intergenerational trauma

Culturally Safe Care Principles

Yarning and relationship-building
Invest time in building rapport and trust. Use yarning-based consultations. Acknowledge and respect cultural protocols. Recognise that health literacy varies — avoid jargon, use visual aids and plain language, and involve family/kinship networks in care planning.
Aboriginal Health Workers & Practitioners (AHW/P)
AHWPs are essential to culturally safe diabetes care. They provide education, care coordination, clinical care (blood glucose monitoring, foot screening, injection support), and cultural brokerage. Refer through Aboriginal Community Controlled Health Organisations (ACCHOs) wherever possible.
Aboriginal Community Controlled Health Organisations (ACCHOs)
ACCHOs deliver comprehensive primary care to approximately 40% of the Indigenous population. They provide holistic, community-controlled care that integrates clinical management with social and emotional wellbeing. Support patient engagement with ACCHO services where available.
Remote and very remote access
Specialist endocrinology, ophthalmology (retinal screening), podiatry, and dietetics services are limited in remote areas. Utilise the RFDS, visiting specialist programmes, telehealth (MBS items 99200–99215 for telehealth consultations), and Patient-Assisted Travel Schemes (PATS). Optometry outreach programmes for retinal screening are critical.
Medication access and adherence
PBS Close the Gap (CTG) scripts — eligible Indigenous Australians receive PBS medicines at concessional co-payment rate (.70 or free) regardless of concession card status. CTG scripts are available through all pharmacies. Remote communities may face supply chain issues — Remote Area Aboriginal Health Services can hold medication stocks under Section 100 arrangements. Cold-chain for insulin is challenging in remote settings — use insulated containers and community health centre fridges.
Chronic Disease Management items (MBS)
Use MBS 715 (Annual Health Assessment for Aboriginal and Torres Strait Islander peoples — comprehensive, bulk-billed, no age restriction). MBS 721 (GPMP) and 723 (TCA) for care planning. MBS 2517 for annual diabetes review. MBS 10987 allows GPs to claim for health assessments conducted by AHWPs under supervision.
Indigenous-specific programmes
National Aboriginal and Torres Strait Islander Flexible Aged Care Program. Tackling Indigenous Smoking programme. Indigenous Australians Health Programme (IAHP). Diabetes Australia's Indigenous-specific resources. The Deadly Choices programme for youth health promotion.

Management Recommendations Specific to Indigenous Populations

  • Screen aggressively: Annual screening from age 18 (or younger if risk factors). Use MBS 715 for comprehensive health assessments including diabetes screening.
  • Start metformin early: Often needed alongside lifestyle intervention at diagnosis given the high metabolic risk profile. Ensure CTG scripts for affordable access.
  • Renal monitoring: Diabetic kidney disease is the leading cause of ESKD in Indigenous Australians. Monitor eGFR and ACR at least 6-monthly (not just annually). SGLT2 inhibitors (empagliflozin, dapagliflozin) should be strongly considered for renal protection — ensure PBS Authority access.
  • Cardiovascular risk management: Absolute cardiovascular risk is very high. High-intensity statin therapy for all Indigenous adults with T2DM aged ≥50. ACE inhibitors/ARBs for hypertension + albuminuria. Smoking cessation is a priority.
  • Foot care: Rates of diabetes-related amputation are 6–12 times higher. Prioritise foot screening, podiatry referral (visiting or telehealth), and culturally appropriate footwear programmes. Coordinate with ACCHOs.
  • Retinal screening: Digital retinal photography through outreach programmes (e.g., Lions Eye Institute outreach, state-based diabetic retinal screening programmes). Telehealth retinal grading enables remote specialist review.
  • Food security: Advocate for improved access to affordable, nutritious food in remote communities. Support community gardens and nutrition programmes. Refer to nutritionists with Indigenous health expertise.

📚 References

  1. 1. Royal Australian College of General Practitioners (RACGP). Management of type 2 diabetes: A handbook for general practice. Melbourne: RACGP; 2020. Updated 2023.
  2. 2. Australian Institute of Health and Welfare (AIHW). Diabetes: Australian facts. Canberra: AIHW; 2023. Cat. no. CVD 86.
  3. 3. Australasian Diabetes in Pregnancy Society (ADIPS). ADIPS consensus guidelines for the testing and diagnosis of gestational diabetes mellitus in Australia and New Zealand. Australasian Diabetes in Pregnancy Society; 2014.
  4. 4. International Society for Pediatric and Adolescent Diabetes (ISPAD). ISPAD clinical practice consensus guidelines 2024. Pediatr Diabetes. 2024;25(Suppl 28).
  5. 5. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–1966.
  6. 6. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). N Engl J Med. 2015;373(22):2117–2128.
  7. 7. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844.
  8. 8. Department of Health and Aged Care, Australian Government. MBS Online — Medicare Benefits Schedule. Canberra: Department of Health; 2024. Available at: www.mbsonline.gov.au.
  9. 9. Diabetes Australia. National Diabetes Services Scheme (NDSS). Canberra: Diabetes Australia; 2024. Available at: www.ndss.com.au.
  10. 10. Australian Government Department of Health. Pharmaceutical Benefits Scheme (PBS) — Diabetes medications. Canberra: Department of Health; 2024. Available at: www.pbs.gov.au.
  11. 11. National Health and Medical Research Council (NHMRC). National evidence-based guideline for diagnosis, prevention and management of chronic kidney disease in type 2 diabetes. Canberra: NHMRC; 2009 (updated recommendations via Kidney Health Australia 2020).
  12. 12. Kidney Health Australia. Kidney disease management in primary care: Caring for Australasians with renal impairment. 4th ed. Melbourne: Kidney Health Australia; 2020.
  13. 13. Diabetes Australia, Royal Australian College of General Practitioners, Australasian Diabetes Educators Association. National evidence-based guideline for the primary prevention of type 2 diabetes. Canberra: Diabetes Australia; 2009.
  14. 14. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework: Diabetes. Canberra: AIHW; 2023.
  15. 15. Marso SP, Daniels GH, Frandsen KB, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311–322.
  16. 16. American Diabetes Association Professional Practice Committee. Standards of care in diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S1–S321.
  17. 17. Australian Diabetes Society (ADS). Position statement: Individualisation of HbA1c targets for adults with diabetes mellitus. Sydney: ADS; 2023.
  18. 18. NPS MedicineWise. Managing type 2 diabetes: an update on pharmacological options. Sydney:
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).